The stock has a 36-month beta value of 1.12. Opinions on the stock are mixed, with 1 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for BCTX is 6.34M, and at present, short sellers hold a 3.32% of that float. On July 04, 2025, the average trading volume of BCTX was 1.53M shares.
BCTX stock’s latest price update
BriaCell Therapeutics Corp (NASDAQ: BCTX)’s stock price has plunge by -0.68%relation to previous closing price of $2.93. Nevertheless, the company has seen a -6.43% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-02 that PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.
BCTX’s Market Performance
BriaCell Therapeutics Corp (BCTX) has seen a -6.43% fall in stock performance for the week, with a -14.66% decline in the past month and a -19.39% plunge in the past quarter. The volatility ratio for the week is 5.03%, and the volatility levels for the past 30 days are at 5.79% for BCTX. The simple moving average for the past 20 days is -7.35% for BCTX’s stock, with a -58.51% simple moving average for the past 200 days.
Analysts’ Opinion of BCTX
Many brokerage firms have already submitted their reports for BCTX stocks, with H.C. Wainwright repeating the rating for BCTX by listing it as a “Buy”. The predicted price for BCTX in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on February 14, 2022 of the previous year 2022.
BCTX Trading at -16.17% from the 50-Day Moving Average
After a stumble in the market that brought BCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.10% of loss for the given period.
Volatility was left at 5.79%, however, over the last 30 days, the volatility rate increased by 5.03%, as shares sank -11.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.61% lower at present.
During the last 5 trading sessions, BCTX fell by -6.43%, which changed the moving average for the period of 200-days by -65.39% in comparison to the 20-day moving average, which settled at $3.14. In addition, BriaCell Therapeutics Corp saw -82.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of BriaCell Therapeutics Corp, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for BCTX
The total capital return value is set at -6.61%. Equity return is now at value -602.61%, with -167.50% for asset returns.
Currently, EBITDA for the company is -4.77 million with net debt to EBITDA at 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.41.
Conclusion
To sum up, BriaCell Therapeutics Corp (BCTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
